
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Rationale for PD-1 with BCG in NMIBC
Terence Friedlander outlines immunologic and clinical reasons to combine PD-1 inhibitors with BCG in frontline high-risk NMIBC.
Play episode from 01:05
Transcript


